View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
July 8, 2012

Pfizer defends itself against Lipitor lawsuit

Pfizer has vowed to "vigorously" defend itself against claims that it conspired with India's Ranbaxy Laboratories to delay sales of generic versions of Lipitor, the world's best selling drug.

By Nikitha Ladda

Pfizer HQ

Pfizer has vowed to "vigorously" defend itself against claims that it conspired with India’s Ranbaxy Laboratories to delay sales of generic versions of Lipitor, the world’s best selling drug.

Five US filed a lawsuit against the companies on 5 July 2012 in New Jersey, accusing the companies of an "overarching anticompetitive scheme" to keep generic versions of the cholesterol drug off the market until November 30 2011, 20 months after the original patent expired, reports Reuters.

Walgreen Co, Kroger Co, Safeway Inc, SuperValu and HEB Grocery Co said the defendants obtained a fraudulent patent, entered a price-fixing agreement to delay cheater generics and entered arrangements with pharmacy benefit managers to force retailers to buy more Lipitor (atorvastatin calcium).

Pfizer denies the plaintiffs’ claims and will defend itself vigorously, spokesman Christopher Loder told the news agency.

"We are confident that Pfizer’s procurement and enforcement of its Lipitor patents was at all times proper and lawful," he added.

Lipitor sales in 2011 totalled $9.6bn, but in the first quarter of 2012, the drug’s sales fell about 42% to $1.4bn from $2.39bn a year earlier, a drop that Pfizer attributed to the loss of US exclusivity.


Image: Pfizer’s world headquarters in Manhattan, New York.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology